Microbubble Complexes for Targeted Sonodynamic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for deeply-seated tumors, such as pancreatic cancer, are invasive and associated with significant side effects, limiting their efficacy and accessibility, especially for tumors that are difficult to reach with conventional light-based therapies like PDT.
Innovation Solution
The development of microbubble complexes that simultaneously deliver a sonosensitizer and an anti-metabolite using ultrasound, allowing for targeted sonodynamic therapy (SDT) with reduced side effects by using a microbubble as a carrier to focus both agents at the tumor site, enhancing drug loading and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (surgery, chemotherapy, radiotherapy) are used for deeply-seated tumors, then treatment coverage is achieved, but patient morbidity and side effects increase significantly
Solution Approach 1:
The treatment approach is segmented into multiple components: microbubbles as carriers, sonosensitizers as active agents, and focused ultrasound as the activation source. This segmentation allows each component to be optimized independently while reducing overall treatment invasiveness compared to conventional single-modality approaches.
Solution Approach 2:
Microbubbles serve as intermediaries that carry sonosensitizers to the tumor site and convert ultrasound energy into localized cytotoxic effects. This intermediary mechanism enables non-invasive delivery and activation, avoiding the direct invasiveness of surgery and the systemic side effects of chemotherapy.
2Reliability
If photodynamic therapy (PDT) is used for superficial tumors, then treatment efficacy is achieved, but penetration depth is limited to a few millimeters
Solution Approach 1:
The patent replaces the optical activation mechanism of PDT with acoustic activation using ultrasound. This substitution allows penetration into deeply-seated tumors because ultrasound waves can propagate through tens of centimeters of tissue, unlike visible light which is limited to a few millimeters.
Solution Approach 2:
The activation wavelength is changed from visible light (400-700 nm) to ultrasound frequencies (typically 1-10 MHz). This parameter change enables deep tissue penetration while maintaining the photodynamic/sonodynamic mechanism of reactive oxygen species generation.
3Length of stationary object
If catheter-directed fiber optic devices are used for deep tumor activation, then deeper target cell access is achieved, but the procedure becomes complicated and invasive
Solution Approach 1:
The patent extracts the activation source from the body (external ultrasound transducer) rather than inserting it via catheters. This eliminates the need for complex catheter-directed fiber optic procedures while achieving deep tumor activation through the non-invasive external application of ultrasound.
Solution Approach 2:
The microbubbles themselves serve as the focal point for ultrasound activation, concentrating the therapeutic effect at the tumor site without requiring external guidance systems or complex positioning devices. The microbubbles naturally accumulate in the tumor vasculature and convert ultrasound energy locally.
4Reliability
If photosensitizers absorbing visible light are used, then PDT activation is achieved, but tissue penetration is restricted to superficial areas
Solution Approach 1:
The patent substitutes optical activation with acoustic activation, replacing photosensitizers that absorb visible light with sonosensitizers that are activated by ultrasound. This substitution expands the treatable tissue area from superficial regions to deeply-seated tumors throughout the body.
5Reliability
If multiple separate treatments (surgery, chemotherapy, radiotherapy) are applied, then comprehensive cancer treatment is achieved, but treatment time and patient burden increase
Solution Approach 1:
The patent merges delivery and activation into a single integrated process: microbubbles carrying sonosensitizers are injected, accumulate in the tumor, and are activated by external ultrasound. This combines what would otherwise require separate administration and activation steps into one non-invasive procedure.
Solution Approach 2:
The microbubble-sonosensitizer complex serves multiple functions simultaneously: it acts as a delivery vehicle, a contrast agent for ultrasound imaging, and a source of cytotoxic reactive oxygen species upon activation. This multi-functionality consolidates multiple therapeutic and diagnostic functions into a single treatment platform.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables effective, non-invasive treatment of deeply-seated tumors with reduced side effects by using microbubbles to deliver both sonosensitizers and anti-metabolites, improving treatment outcomes for pancreatic cancer and potentially other hyperproliferative conditions.
Implementation Method 1
activation of the sonosensitiser by acoustic energy results in the generation of reactive oxygen species (ROS), such as singlet oxygen, at the target site of interest
Implementation Method 2
ultrasound energy can also be focused on a tumour mass in order to activate the sonosenitiser thereby restricting its effects to the target site
Implementation Method 3
injection of ultrasound-responsive microbubbles (MB) filled with gaseous oxygen and bearing a Rose Bengal sensitiser provides a statistically significant SDT-mediated reduction in tumour growth
Data Source
AI summary
The invention relates to microbubble complexes for use in methods of sonodynamic therapy which comprise a microbubble attached to or otherwise associated with one or more linking groups, each linking group being bound to at least one sonosensitising agent and at least one chemotherapeutic agent. It further relates to the microbubble complexes themselves and to pharmaceutical compositions which contain them. The invention is particularly suitable for the treatment of deep-sited tumors, in particular pancreatic cancer.